← Back to Search

Corticosteroid

Atomoxetine for Attention Deficit Hyperactivity Disorder (ADHD)

Phase 3
Waitlist Available
Led By Floyd R Sallee, MD
Research Sponsored by University of Cincinnati
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be younger than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 2 hours (at baseline visit)
Awards & highlights

Study Summary

The purpose of this study is to find out if children with attention-deficit, hyperactivity disorder (ADHD) have a difference in how their brain cells "fire" or react. The investigators also want to find if brain cell "firing" can tell us how severe of symptoms a child has from ADHD. Finally, the investigators want to see if giving an ADHD medication called atomoxetine can make the ADHD symptoms in a child better and if the improvement shows a change in brain "firing".

Eligible Conditions
  • Attention Deficit Hyperactivity Disorder (ADHD)

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~at 4 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and at 4 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Cognitive Correlates of SICI Change
Efficacy outcome as change from baseline in ADHDRS total score
SICI as a marker of ADHD Behaviors

Trial Design

2Treatment groups
Active Control
Placebo Group
Group I: AtomoxetineActive Control1 Intervention
Atomoxetine is FDA-approved for the treatment of ADHD symptoms in children
Group II: PlaceboPlacebo Group1 Intervention
Sugar pill

Find a Location

Who is running the clinical trial?

University of CincinnatiLead Sponsor
428 Previous Clinical Trials
634,274 Total Patients Enrolled
5 Trials studying Attention Deficit Hyperactivity Disorder (ADHD)
863 Patients Enrolled for Attention Deficit Hyperactivity Disorder (ADHD)
National Institute of Mental Health (NIMH)NIH
2,786 Previous Clinical Trials
2,689,572 Total Patients Enrolled
94 Trials studying Attention Deficit Hyperactivity Disorder (ADHD)
19,925 Patients Enrolled for Attention Deficit Hyperactivity Disorder (ADHD)
Floyd R Sallee, MDPrincipal InvestigatorUniversity of Cincinnati

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Cortical Excitability: Phenotype and Biomarker in Attention-deficit, Hyperactivity Disorder (ADHD) Therapy
Floyd Sallee 2009. "Cortical Excitability: Phenotype and Biomarker in Attention-deficit, Hyperactivity Disorder (ADHD) Therapy". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT01330693.
All > Adhd
~8 spots leftby May 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top